This suggests that EcNPAQ inhibits tumor growth by blocking the PD‐1/PD‐L1 pathway, further promoting T cell infiltration into tumor tissues.[55] Additionally, we evaluated the proportion of mIFN‐γ‐producing CD8+ T cells in tumor tissue and found a significant increase in this population in the EcNPAQ group compared to the other treatment groups (Figure 6C). The gene discussed is CD8A; the disease is neoplasm.